---
title: "Psilocybin (COMP360) in Treatment-resistant depression: COMP006"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: COMP006. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 68 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/comp006"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: COMP006

<a id="heading-3.1.2"></a>

## 3.1.2 COMP006

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registered objective

> “Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)”
> “In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.1-2"></a>

#### Objective of the second dose and the 10 mg arm

> “This trial is designed to investigate if a second dose can increase the number of responders and/or improve response seen in the Company’s Phase 2b study and explore the potential for a meaningful treatment response from repeat administration of COMP360 10mg.”

Source: [COMPASS Pathways phase 3 design release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-Announces-Phase-3-Pivotal-Program-Design-for-COMP360-in-Treatment-Resistant-Depression-at-Capital-Markets-Day/default.aspx)

> “Pivotal trial 2 (COMP006) (n=581): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg. This trial is designed to investigate whether a second dose can increase therapeutic response.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates

> “Study Start (Actual) 2023-02-14”
> “Primary Completion (Actual) 2025-11-13”
> “Study Completion (Estimated) 2026-12”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.2-2"></a>

#### Sites and countries

> “This study has 116 locations”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The second pivotal trial, COMP006, is a randomized, double-blind study with 581 dosed participants across 116 trial sites in the United States, Canada and Europe”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.2.2-3"></a>

#### Completion of enrollment

> “Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

<a id="topic-3.1.2.2-4"></a>

#### Dates of the Part A and Part B results announcements

> “On February 17, 2026, the Company announced the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “On July 7, 2026, the Company announced the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression, or TRD”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Phase 3, randomized, double-blind, dose-controlled parallel-group design

> “This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study.”
> “Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “In COMP006, participants were randomized 2:1:1 to two doses (3 weeks apart) of COMP360 25 mg, 10 mg, or 1 mg.”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.3-2"></a>

#### Three study parts over 52 weeks

> “The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period. Part A will include a nine-week follow-up from initial investigational product (IP) administration. Part B will include a further 17 weeks follow-up out to 26 weeks from initial IP administration. Part C will include a further 26 weeks follow-up out to 52 weeks from initial IP administration.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The trial is comprised of three parts: Part A, which was blinded through 9 weeks, Part B which recently concluded and remained blinded through week 26, and Part C, which contains an open-label treatment part from week 26 to 52.”
> “There is a potential for a total of 4 doses of COMP360 across a 52-week period.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.3-3"></a>

#### Retreatment and concomitant antidepressants in Parts B and C

> “Part A (blinded) 9 weeks Part B (blinded) 17 weeks Part C (open label) 26 weeks”
> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements. Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”
> “retreatment based on pre-specified criteria and receive either what they were randomized into or antidepressant”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.3-4"></a>

#### Protocol amendments discussed with FDA

> “We have Breakthrough Therapy Designation and have had dialogue with the FDA regarding our Phase 3 trial design, including certain protocol amendments that we implemented in the first half of 2023.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion criteria

> “Aged ≥18 years at Screening”
> “Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5])”
> “If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening”
> “MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression”
> “TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ”
> “At Screening, agreement to discontinue all prohibited medications”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “Adults with TRD (2-4 inadequate prior treatment responses) were enrolled.”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria

> “Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)”
> “Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module”
> “Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)”
> “Psychiatric inpatient within the past 12 months prior to Screening”
> “Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode”
> “Transcranial magnetic stimulation within the past six months prior to Screening”
> “Exposure to COMP360 psilocybin therapy prior to Screening”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.4-3"></a>

#### Planned limit on prior psychedelic experience

> “planned limit for prior psychedelic experience in trial was 15%”

Source: [COMPASS Pathways COMP006 26-week presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Study arms

> “Experimental: 25 mg COMP360 Psilocybin”
> “Experimental: 10 mg COMP360 Psilocybin”
> “Active Comparator: 1 mg COMP360 Psilocybin”
> “COMP360 Psilocybin administered under supportive conditions”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.5-2"></a>

#### Two fixed doses three weeks apart in Part A

> “is comparing the efficacy and safety of two fixed doses, taken three weeks apart, of 25 mg COMP360 to 10 mg COMP360 and 1 mg COMP360”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.5-3"></a>

#### Retreatment doses in Parts B and C

> “those who meet criteria for re-treatment will have the option to receive an additional treatment dose according to their assigned dose”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Psychological support model

> “In contrast to psychedelic-assisted psychotherapy, COMP360 psilocybin is administered with non-directive psychological support rather than directive psychotherapy.”
> “The Compass Psychological Support Model (CPSM) has been designed as a manualized standard of care in clinical research with COMP360 psilocybin, not to support efficacy, but to safeguard study participants and ensure consistency across multi-site trials.”

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Montgomery-Åsberg Depression Rating Scale Total Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: change from baseline in MADRS total score at Week 6, 25 mg versus 1 mg

> “COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.2.6.1-2"></a>

##### Key secondary endpoint at Week 9

> “Week 9 Key secondary endpoint”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.6.1-3"></a>

##### Registered secondary endpoints

> “COMP360 25 mg versus COMP360 1 mg for the change from baseline in Sheehan Disability Scale (SDS) total score. Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.”
> “COMP360 25 mg versus COMP360 10 mg for the change from baseline in MADRS total score.”
> “COMP360 25 mg versus COMP360 10 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.6.1-4"></a>

##### Sponsor's stated rationale for the MADRS

> “For the MADRS – a more widely used and accepted clinician-rated scale which Compass is using as the primary endpoint in their clinical trials”
> “MADRS, as assessed by independent raters in native language, is a widely accepted assessment of mood disorders.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-3.1.2.6.1-5"></a>

##### FDA guidance on primary endpoints in depression trials

> “Clinician-rated outcome measures are the current standard for assessing efficacy in”
> “To date, the FDA has accepted the following as primary endpoints in phase”
> “Montgomery Asberg Depression Rating Scale”

Source: [FDA (2018)](https://www.fda.gov/media/113988/download)

<a id="topic-3.1.2.6.1-6"></a>

##### MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in treatment-resistant depression

> “In Study 1, the primary efficacy measure was change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at the end of the 4-week double-blind induction phase. The MADRS is a ten-item, clinician-rated scale used to assess severity of depressive symptoms. Scores on the MADRS range from 0 to 60, with higher scores indicating more severe depression.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Development and sensitivity to change of the MADRS

> “Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change.”
> “Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.”

Source: [Montgomery and Asberg (1979)](https://pubmed.ncbi.nlm.nih.gov/444788/)

<a id="topic-3.1.2.6.1-8"></a>

##### Clinically meaningful change in MADRS total score in treatment-resistant depression

> “Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.”

Source: [Turkoz et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7986932/)

> “MCID estimates for MADRS ranged from 1.6 to 1.9.”

Source: [Duru and Fantino (2008)](https://pubmed.ncbi.nlm.nih.gov/18377706/)

<a id="topic-3.1.2.6.1-9"></a>

##### Response and remission definitions on the MADRS

> “Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.”

Source: [Leucht et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28068617/)

> “On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.”

Source: [Zimmerman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15003068/)

<a id="topic-3.1.2.6.1-10"></a>

##### Sponsor's definitions of remission and clinically meaningful reduction in COMP006

> “Remitters (n=48) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=68) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=153) = % CFB in MADRS ≤ 25%”
> “Clinically meaningful reduction in MADRS defined as a ≥25% reduction from baseline in MADRS total score at Week 6. This graph is a post hoc analysis.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.6.1-11"></a>

##### Rationale for the 1 mg active control and the 10 mg arm

> “COMP006 addresses some of the functional unblinding risks of an inert placebo-control by comparing the safety and efficacy of 25 mg COMP360 to a low active control dose of COMP360 (1 mg), while also including a moderately psychoactive active treatment arm (10 mg COMP360 psilocybin).”
> “Ongoing trials with investigational COMP360 psilocybin (COMP005 and COMP006) include several design elements to help address these considerations and align with FDA draft guidance on clinical trials with psychedelics.”

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf)

<a id="topic-3.1.2.6.1-12"></a>

##### FDA guidance on control groups in psychedelic drug trials

> “Given concerns for functional unblinding, the use of a traditional placebo as a control can be problematic for assessing efficacy even though it provides better contextualization for safety findings.”
> “Alternatives to an inert placebo (e.g., lower doses of a psychedelic, other psychoactive drugs that mimic some aspects of the subjective experience associated with psychedelic drugs) may be considered as well.”
> “For example, a trial using a low, middle, and high dose without a placebo could be paired with a placebo-controlled trial. The trial without a placebo could provide information about dose-response with less risk of functional unblinding.”
> “Sponsors should incorporate the use of central raters blinded to treatment allocation and visit number.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.6.1-13"></a>

##### Use of a 1 mg psilocybin dose as an active control in earlier trials

> “In previous clinical trials, a dose of 1 mg of psilocybin or a dose range of 1-3 mg/70 kg were used as an active control because these doses were believed not to produce significant psychedelic effects.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

> “we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

> “Active placebos, either low-dose psychedelics or alternative psychoactive medications (particularly those which induce a distinct but similarly profound psychoactive effect), likely provide a means of mitigating the expectancy effects”

Source: [Butler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481484/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment

> “Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg.”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

> “Pivotal trial 2 (COMP 006) (n= 568): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg.”

Source: [COMPASS Pathways phase 3 design release (2022)](https://ir.compasspathways.com/News--Events-/news/news-details/2022/COMPASS-Pathways-Announces-Phase-3-Pivotal-Program-Design-for-COMP360-in-Treatment-Resistant-Depression-at-Capital-Markets-Day/default.aspx)

<a id="topic-3.1.2.7.1-2"></a>

##### Actual enrollment in the registry record

> “Enrollment (Actual) 572”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants dosed, as reported by the company

> “is a randomized, double-blind study with 581 dosed participants across North America and Europe and is comparing the efficacy and safety of two fixed doses, taken three weeks apart, of 25 mg COMP360 to 10 mg COMP360 and 1 mg COMP360 (25 mg: n=296; 10 mg: n=142; 1 mg: n=143).”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “In COMP006 (n=581), two doses of 25 mg significantly reduced MADRS scores at Week 6 versus 1 mg”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Safety analysis set

> “N=number of participants in the treatment group in the Safety Analysis Set by administration; n = number of participants.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Note: COMP006 safety includes 2 dose administrations and goes out to 9 weeks vs. 1 administration out to 6 weeks for COMP005”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.7.2-2"></a>

##### Efficacy analyses: least squares means in Part A and observed data in Part B

> “Change from baseline (Least square mean in Part A, Observed mean in Part B) +95% CIs”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Responder analysis population

> “This graph is a post hoc analysis. Total n at 6 weeks = 269 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participants dosed by arm

> “(25 mg: n=296; 10 mg: n=142; 1 mg: n=143)”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.1-2"></a>

##### Participants in the 25 mg arm assessed at Week 6 and retreated in Part B

> “Total n at 6 weeks = 269 (based on ITT)”
> “58% of patients in 25mg arm received retreatment after Week 9”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.1-3"></a>

##### Results posting status in the registry

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographics

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Female, n (%) | “160 (54.1)” | “68 (47.9)” | “69 (48.3)” |
| White, n (%) | “255 (86.1)” | “123 (86.6)” | “129 (90.2)” |
| Asian, n (%) | “14 (4.7)” | “6 (4.2)” | “6 (4.2)” |
| Black or African American, n (%) | “8 (2.7)” | “3 (2.1)” | “4 (2.8)” |
| American Indian or Alaska Native, n (%) | “0” | “0” | “1 (0.7)” |
| Other/not reported, n (%) | “19 (6.4)” | “10 (7.0)” | “3 (2.1)” |
| Age, years, mean (SD) | “46.2 (13.7)” | “42.9 (12.8)” | “45.5 (13.1)” |
| Age, min, max | “18, 79” | “19, 73” | “20, 75” |
| Age ≥65 years, n (%) | “29 (9.8)” | “9 (6.3)” | “13 (9.1)” |
| Prior psilocybin experience, n (%) | “12 (4.1)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “20 (6.8)” | “8 (5.6)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.4 (6.4)” | “28.0 (6.5)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-2"></a>

##### Treatment history and baseline MADRS

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Failed treatments in current episode: 1, n (%) | “1 (0.3)” | “1 (0.7)” | “0” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “98 (68.5)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “34 (23.8)” |
| Failed treatments in current episode: 4, n (%) | “29 (9.8)” | “4 (2.8)” | “11 (7.7)” |
| Failed treatments in current episode: 5, n (%) | “2 (0.7)” | “0” | “0” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “30 (21.1)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “62 (43.7)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “34 (23.9)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “16 (11.3)” | “14 (9.8)” |
| MADRS total score at baseline, mean (SD) | “32.0 (5.8)” | “32.1 (5.8)” | “32.5 (5.4)” |
| Baseline MADRS subthreshold (≤10), n (%) | “2 (0.7)” | “0” | “0” |
| Baseline MADRS mild (11-19), n (%) | “0” | “0” | “0” |
| Baseline MADRS moderate (20-30), n (%) | “115 (38.9)” | “54 (38.0)” | “49 (34.3)” |
| Baseline MADRS severe (≥31), n (%) | “179 (60.5)” | “88 (62.0)” | “94 (65.7)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-3"></a>

##### Depression diagnosis history

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Length of current episode, months, mean (SD) | “45.5 (42.7)” | “37.7 (38.8)” | “38.4 (45.0)” |
| Length of current episode less than 1 year, n (%) | “53 (17.9)” | “37 (26.1)” | “30 (21.0)” |
| Length of current episode 1-2 years, n (%) | “73 (24.7)” | “35 (24.6)” | “41 (28.7)” |
| Length of current episode more than 2 years, n (%) | “170 (57.4)” | “70 (49.3)” | “72 (50.3)” |
| Lifetime depressive episodes, mean (SD) | “6.3 (7.4)” | “5.4 (6.6)” | “7.0 (12.5)” |
| Lifetime depressive episodes: 1, n (%) | “1 (0.3)” | “0” | “0” |
| Lifetime depressive episodes: 2-5, n (%) | “199 (67.2)” | “109 (76.8)” | “99 (69.2)” |
| Lifetime depressive episodes: 6-10, n (%) | “61 (20.6)” | “21 (14.8)” | “30 (21.0)” |
| Lifetime depressive episodes: more than 10, n (%) | “29 (9.8)” | “10 (7.0)” | “10 (7.0)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.2-4"></a>

##### Chronicity of the enrolled population

> “In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.2-5"></a>

##### Baseline values that differ in the February 2026 presentation

| Characteristic | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Prior psilocybin experience, n (%) | “13 (4.4)” | “5 (3.5)” | “5 (3.5)” |
| Prior psychedelic experience including psilocybin, n (%) | “19 (6.4)” | “7 (4.9)” | “9 (6.3)” |
| BMI, kg/m2, mean (SD) | “28.0 (6.2)” | “28.6 (7.1)” | “27.8 (6.7)” |
| Failed treatments in current episode: 2, n (%) | “190 (64.2)” | “105 (73.9)” | “99 (69.2)” |
| Failed treatments in current episode: 3, n (%) | “74 (25.0)” | “32 (22.5)” | “33 (23.1)” |
| Treatments withdrawn in screening: 0, n (%) | “68 (23.0)” | “31 (21.8)” | “36 (25.2)” |
| Treatments withdrawn in screening: 1, n (%) | “127 (42.9)” | “61 (43.0)” | “62 (43.4)” |
| Treatments withdrawn in screening: 2, n (%) | “68 (23.0)” | “35 (24.6)” | “31 (21.7)” |
| Treatments withdrawn in screening: more than 2, n (%) | “33 (11.1)” | “15 (10.6)” | “14 (9.8)” |
| Lifetime depressive episodes: 2-5, n (%) | “198 (66.9)” | “109 (76.8)” | “99 (69.2)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Part A primary endpoint: MADRS change at Week 6, 25 mg versus 1 mg

> “Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint.”
> “Primary endpoint of Part A: Two doses of COMP360 25 mg versus 1 mg with a mean treatment difference of -3.8 points, 95% CI [-5.8, -1.8]; p<0.001 at Week 6”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “two doses of 25 mg significantly reduced MADRS scores at Week 6 versus 1 mg (LSMD: -3.8; 95% CI: -5.8, -1.8;”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.8.3-2"></a>

##### Part A: MADRS least squares mean differences by visit through Week 6, November 2026 presentation

| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
| --- | --- | --- | --- | --- |
| Day 2 | “-2.9 (-4.6, -1.2)” | “<0.001” | “-3.0 (-5.0, -1.0)” | “0.002” |
| Week 1 | “-5.0 (-7.0, -3.0)” | “<0.001” | “-3.5 (-5.9, -1.2)” | “0.001” |
| Week 3 | “-4.4 (-6.3, -2.5)” | “<0.001” | “-3.4 (-5.6, -1.2)” | “0.001” |
| Day 24 | “-5.0 (-7.1, -2.9)” | “<0.001” | “-4.9 (-7.4, -2.5)” | “<0.001” |
| Week 4 | “-4.8 (-6.9, -2.7)” | “<0.001” | “-4.9 (-7.3, -2.5)” | “<0.001” |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.8, -0.2)” | “0.017” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Statistically significant treatment differences in 25mg vs 1mg and 10mg vs 1 mg found at all timepoints post administration”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-3"></a>

##### Part A: 10 mg versus 1 mg at Week 6, as reported in February and September 2026

> “the 10 mg dose showed a smaller effect (LSMD: -2.5; 95% CI: -4.9, -0.2; p=0.016)”

Source: [Psych Congress Elevate phase 3 primary endpoint abstract (2026)](https://www.hmpgloballearningnetwork.com/node/378891)

<a id="topic-3.1.2.8.3-4"></a>

##### Part A key secondary endpoint: MADRS change at Week 9

| Visit | 25 mg vs 1 mg, LS mean difference (95% CI) | 25 mg vs 1 mg, P-value | 10 mg vs 1 mg, LS mean difference (95% CI) | 10 mg vs 1 mg, P-value |
| --- | --- | --- | --- | --- |
| Week 6 (primary) | “-3.8 (-5.8, -1.8)” | “<0.001” | “-2.5 (-4.9, -0.2)” | “0.016” |
| Week 9 (secondary) | “-2.9 (-5.0, -0.9)” | “0.002” | “-2.6 (-5.0, -0.2)” | “0.016” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

> “Statistical significance maintained through Week 9”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.3-5"></a>

##### Part A post hoc responder analysis at Week 6, 25 mg arm

> “39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “Remitters (n=48) = MADRS ≤12 and no single item ≥4; Responders and Partial Responders (n=68) = % CFB in MADRS ≥ 25% and do not meet remission criterion; Non-Responder (n=153) = % CFB in MADRS ≤ 25%”
> “This graph is a post hoc analysis. Total n at 6 weeks = 269 (based on ITT)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-6"></a>

##### Part B: MADRS change through Week 26

> “Rapid onset of effect was observed, with consistent separation between the 25 mg and the 1 mg arm maintained through the randomized, blinded Part B period to Week 26”
> “39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6, maintaining benefit, on average, through at least Week 26”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

> “Persistent treatment effect of 25mg arm over full 26 weeks”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.3-7"></a>

##### Part B: retreatment and remission after retreatment

> “58% of patients in 25mg arm received retreatment after Week 9”
> “28% of those who achieved clinically meaningful reduction in MADRS but had not remitted by 6 weeks went into remission after additional dose in Part B”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Retreatment in Part B further enhanced benefit: nearly 30% of participants who achieved a clinically meaningful response at Week 6 later went into remission”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Part A safety summary

> “Most TEAEs occurred on the days of study drug administration (73%) with the vast majority (83%) resolving within a day”
> “Most common TEAEs were headache, nausea, anxiety and visual hallucination”
> “There were 6 treatment-emergent serious adverse events (SAEs) from 6 participants (2%) overall”
> “Across both trials, for the data available to date, the rate for SAE suicidal ideation was less than 1%. There was only one event of SAE suicidal behavior, which occurred in the 1 mg arm in COMP006.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

> “To date there have been no attempted or completed suicides”
> “The DSMB noted that there is no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study”

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-2"></a>

##### Part A treatment-emergent adverse events through Week 9

| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE up to Week 9, n (%) | “274 (92.6)” | “125 (88.0)” | “116 (81.1)” |
| Any serious TEAE up to Week 9, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Any TEAE with onset on day of dosing, n (%) | “260 (87.8)” | “114 (80.3)” | “80 (55.9)” |
| Resolved ≤1 day, n (%) | “244 (82.4)” | “107 (75.4)” | “71 (49.7)” |
| Resolved >1 and ≤2 days, n (%) | “52 (17.6)” | “16 (11.3)” | “9 (6.3)” |
| Resolved >2 days, n (%) | “71 (24.0)” | “26 (18.3)” | “20 (14.0)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-3"></a>

##### Part A TEAEs with incidence above 10%

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE, n (%) | “254 (85.8)” | “111 (78.2)” | “80 (55.9)” |
| Nausea, n (%) | “118 (39.9)” | “42 (29.6)” | “15 (10.5)” |
| Headache, n (%) | “108 (36.5)” | “43 (30.3)” | “41 (28.7)” |
| Anxiety, n (%) | “62 (20.9)” | “28 (19.7)” | “21 (14.7)” |
| Hallucination, visual, n (%) | “46 (15.5)” | “24 (16.9)” | “3 (2.1)” |
| Illusion, n (%) | “41 (13.9)” | “16 (11.3)” | “3 (2.1)” |
| Dizziness, n (%) | “41 (13.9)” | “21 (14.8)” | “9 (6.3)” |
| Fatigue, n (%) | “41 (13.9)” | “23 (16.2)” | “16 (11.2)” |
| Crying, n (%) | “35 (11.8)” | “13 (9.2)” | “4 (2.8)” |
| Blood pressure increased, n (%) | “31 (10.5)” | “6 (4.2)” | “4 (2.8)” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-4"></a>

##### Part A treatment-emergent serious adverse events

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any SAE, n (%) | “6 (2.0)” | “1 (0.7)” | “5 (3.5)” |
| Suicidal ideation, n (%) | “0” | “1 (0.7)” | “2 (1.4)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |

Source: [COMPASS Pathways COMP006 topline presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/exhibit991investorpresen.htm)

<a id="topic-3.1.2.8.5-5"></a>

##### Safety summary through Week 26

> “Majority of TEAEs were transient and predominantly occurring on day of dosing”
> “Most common adverse events were nausea, headache, anxiety and visual hallucination”
> “Serious adverse events (SAEs) were similar across arms (6.3% in the 1 mg arm and 5.7% in the 25 mg arm) over 26 weeks but low overall across the trial”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-3.1.2.8.5-6"></a>

##### Treatment-emergent adverse events through Week 26

| Measure | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TEAE up to Week 26, n (%) | “280 (94.6)” | “132 (93.0)” | “124 (86.7)” |
| Any serious TEAE up to Week 26, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Any TEAE with onset on day of dosing, n (%) | “265 (89.5)” | “119 (83.8)” | “88 (61.5)” |
| Resolved ≤1 day, n (%) | “255 (86.1)” | “113 (79.6)” | “78 (54.5)” |
| Resolved >1 and ≤2 days, n (%) | “60 (20.3)” | “22 (15.5)” | “12 (8.4)” |
| Resolved >2 days, n (%) | “80 (27.0)” | “32 (22.5)” | “21 (14.7)” |
| Nausea, n (%) | “133 (44.9)” | “50 (35.2)” | “18 (12.6)” |
| Headache, n (%) | “118 (39.9)” | “53 (37.3)” | “49 (34.3)” |
| Anxiety, n (%) | “83 (28.0)” | “38 (26.8)” | “29 (20.3)” |
| Hallucination, visual, n (%) | “51 (17.2)” | “27 (19.0)” | “5 (3.5)” |
| Fatigue, n (%) | “49 (16.6)” | “26 (18.3)” | “19 (13.3)” |
| Illusion or perceptual disturbance, n (%) | “48 (16.2)” | “19 (13.4)” | “4 (2.8)” |
| Dizziness, n (%) | “47 (15.9)” | “25 (17.6)” | “9 (6.3)” |
| Crying, n (%) | “41 (13.9)” | “15 (10.6)” | “6 (4.2)” |
| Blood pressure increased, n (%) | “35 (11.8)” | “10 (7.0)” | “4 (2.8)” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Illusion and Perceptual Disturbance categories have been combined in this presentation due to some recent changes in MedDRA classification”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.8.5-7"></a>

##### Treatment-emergent serious adverse events through Week 26

| MedDRA preferred term | COMP360 25 mg (N=296) | COMP360 10 mg (N=142) | COMP360 1 mg (N=143) |
| --- | --- | --- | --- |
| Any TESAE, n (%) | “17 (5.7)” | “5 (3.5)” | “9 (6.3)” |
| Suicidal ideation, n (%) | “4 (1.4)” | “2 (1.4)” | “4 (2.8)” |
| Suicidal behaviour, n (%) | “0” | “0” | “1 (0.7)” |
| Suspected suicide, n (%) | “1 (0.3)” | “0” | “0” |
| Suicide attempt, n (%) | “0” | “0” | “1 (0.7)” |
| Syncope, n (%) | “1 (0.3)” | “0” | “1 (0.7)” |
| Major depression, n (%) | “1 (0.3)” | “0” | “0” |
| Anxiety, n (%) | “1 (0.3)” | “0” | “0” |
| Flashback, n (%) | “1 (0.3)” | “0” | “0” |
| Cervical spinal stenosis, n (%) | “1 (0.3)” | “0” | “0” |
| Renal neoplasm, n (%) | “0” | “0” | “1 (0.7)” |
| Pelvic pain, n (%) | “1 (0.3)” | “0” | “0” |
| Adjustment disorder with mixed disturbance of emotion and conduct, n (%) | “1 (0.3)” | “0” | “0” |
| Pneumonia, n (%) | “0” | “1 (0.7)” | “0” |
| Radius fracture, n (%) | “1 ( 0.3)” | “1 (0.7)” | “0” |
| Road traffic accident, n (%) | “1 ( 0.3)” | “0” | “0” |
| Tibia fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Ulna fracture, n (%) | “1 ( 0.3)” | “0” | “0” |
| Alanine aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Aspartate aminotransferase increased, n (%) | “1 ( 0.3)” | “0” | “0” |
| Brain neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Thyroid neoplasm, n (%) | “1 (0.3)” | “0” | “0” |
| Cerebrovascular accident, n (%) | “0” | “0” | “1 (0.7)” |
| Toxic encephalopathy, n (%) | “0” | “1 (0.7)” | “0” |
| Tremor, n (%) | “1 (0.3)” | “0” | “0” |

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Suspected Suicide determined by the investigator as not related to the treatment, based on the specific circumstances and timing”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: functional unblinding, low-dose comparator, post hoc and observed-case analyses, preliminary data

COMP006 used COMP360 1 mg as the comparator to address “some of the functional unblinding risks of an inert placebo-control”. FDA guidance states that functional unblinding can lead to expectation bias and that enrolling participants with prior psychedelic exposure raises the possibility of expectation bias; the planned limit for prior psychedelic experience in COMP006 was 15%. One analysis found that outcomes with extremely low dose psilocybin were better than placebo response in psychedelic trials (mean difference 3.96), and a review reported that psilocybin, LSD, and ayahuasca studies “frequently reported blinding failure values of more than 90%” among participants and raters. The responder analysis is post hoc, Part B results after Week 9 are observed data, and protocol-allowed antidepressants were permitted in Parts B and C. The company describes the 26-week results as preliminary and states that full results may not be consistent with them; the registry shows no results posted.

Source: [Young et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Caroline-Hostetler-ASCP-2025.pdf); [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download); [COMPASS Pathways COMP006 26-week presentation (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/a8-kdated7july2026ex991.htm); [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/); [Orsini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41984443/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [ClinicalTrials.gov NCT05711940](https://clinicaltrials.gov/study/NCT05711940)

<a id="topic-3.1.2.9-2"></a>

#### Functional unblinding and expectancy bias, as stated by the company

> “For example, concerns about functional unblinding, expectancy bias or the impact of our model for supporting and monitoring participants in our clinical trials evaluating COMP360 could hinder interpretability or regulatory acceptability of data from clinical trials of our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-3.1.2.9-3"></a>

#### Release of Part A results while Part B remained blinded

> “In addition, as a result of the increased regulatory scrutiny on functional unblinding, the company has decided to shift the data release for COMP006 until after the 26-week time point and the completion of the blinded portion has been reached for all patients to protect against the risk of unblinding.”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

> “Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

> “The trial is comprised of three parts: Part A, which has recently concluded and was blinded through 9 weeks, Part B which remains blinded through week 26, and Part C, which contains an open-label treatment part from week 26 to 52.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-3.1.2.9-4"></a>

#### Preliminary, unpublished data

> “For example, in the first quarter of 2026, we reported preliminary results from our Phase 3 trials in TRD and in the third quarter of 2026, we reported preliminary 26-week results from our Phase 3 COMP006 trial and 52-week results from our Phase 3 COMP005 trial, and the full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-3.1.2.9-5"></a>

#### Post hoc responder analyses, observed-case Part B data, and concomitant antidepressants

> “This graph is a post hoc analysis.”
> “COMP 006 Part B results (post Week 9) are based on observed data only (CFB Mean ± 95% CI)”
> “Participants were permitted to take protocol-allowed antidepressant treatments in Part B and C of the study.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.9-6"></a>

#### Cross-trial comparisons with COMP005

> “Cross-trial comparisons should be interpreted with caution. Differences between trials, including but not limited to study designs, protocols, and timing of assessments. number or timing of doses and participant populations can meaningfully influence outcomes and limit the validity of any comparison.”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-3.1.2.9-7"></a>

#### FDA guidance on functional unblinding and prior psychedelic exposure

> “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit;”
> “Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding.”
> “enrolling individuals with prior psychedelic drug exposure raises the possibility of expectation bias given that participants who have prior experience with psychedelic drugs are more likely to recognize their subjective effects (i.e., leading to functional unblinding) and anticipate a treatment benefit.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-3.1.2.9-8"></a>

#### Blinding failure in psychedelic trials: systematic reviews

> “Functional unblinding was substantial: psilocybin, LSD, and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters, inert placebo-controlled MDMA trials exceeded 85%, and ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls. No control strategy consistently achieved ideal blinding.”

Source: [Orsini et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41984443/)

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

<a id="topic-3.1.2.9-9"></a>

#### Low-dose psilocybin as a comparator: response relative to inert placebo

> “Notably, placebo response in antidepressant trials (3.79 (95% credibile interval 0.77 to 6.80)) and extremely low dose psilocybin (3.96 (0.61 to 7.17)) were better than placebo response in the psychedelic trials, with mean differences exceeding 3 and 95% credibile intervals that did not cross zero.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

> “However, the effect size (standardised mean difference) of high dose psilocybin decreased from large (0.88) to small (0.31) when the reference arm changed from placebo response in the psychedelic trials to antidepressant trials.”

Source: [Hsu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337322/)

<a id="topic-3.1.2.9-10"></a>

#### Mitigation measures proposed in the literature

> “We suggest that simple practical measures may be (and indeed already are) taken in psychedelic trials to partially mitigate the effects of expectancy and unblinding, such as independent raters and active placebos.”

Source: [Butler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9481484/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
